Bioheart ($BHRT):  An Industry Leader and Heart Failure Specialist

Bioheart, Inc. (OTCBB:BHRT, Twitter $BHRT) is a biotechnology company focused 100 percent on cell therapy products for the heart. Specialized as such and led by a team of industry experts, Bioheart offers a full-line of cell therapy products for heart failure to serve their clients and is in the midst of the largest clinical trial of its kind involving congestive heart failure patients.

Bioheart’s flagship technologies, MyoCell and (second generation) MyoCell SDF-1, are myoblasts or muscle stem cells that are intended to improve cardiac function months or even years after a patient has suffered severe heart damage due to a heart attack.  The process involves removing tissue samples from a patient’s thigh muscle which are then processed at the Bioheart laboratories using their proprietary cell-culturing process to isolate stem cells and then injecting them into scar tissue in the patient’s heart to rejuvenate the muscle. Myoblasts are the only stem cell that has shown the ability to grow contractile muscle in scar tissue and that fact is the foundation of this revolutionary therapy.

Presently, the Company is investigating MyoCell in Phase II/III trials under direction of the FDA. The company hopes to capitalize by providing a better quality of life for the more than 25 million people that suffer heart failure today.